APA (7th ed.) Citation

Pham, T. H., Smith, M. A., Alevizos, I., St. Clair, E. W., & Emson, C. (2024). OP0058 DAZODALIBEP (ANTI-CD40L) EFFECTIVELY REDUCES MULTIPLE PROTEINS ASSOCIATED WITH B-, T-, AND DENDRITIC CELL BIOMARKERS IN SJӦGREN’S DISEASE: CORROBORATION OF IMMUNOPHENOTYPING FINDINGS FROM THE ALISS PHASE 2 STUDY. Annals of the rheumatic diseases, 83(Suppl 1), 126-127. https://doi.org/10.1136/annrheumdis-2024-eular.2599

Chicago Style (17th ed.) Citation

Pham, T. H., M. A. Smith, I. Alevizos, E. W. St. Clair, and C. Emson. "OP0058 DAZODALIBEP (ANTI-CD40L) EFFECTIVELY REDUCES MULTIPLE PROTEINS ASSOCIATED WITH B-, T-, AND DENDRITIC CELL BIOMARKERS IN SJӦGREN’S DISEASE: CORROBORATION OF IMMUNOPHENOTYPING FINDINGS FROM THE ALISS PHASE 2 STUDY." Annals of the Rheumatic Diseases 83, no. Suppl 1 (2024): 126-127. https://doi.org/10.1136/annrheumdis-2024-eular.2599.

MLA (9th ed.) Citation

Pham, T. H., et al. "OP0058 DAZODALIBEP (ANTI-CD40L) EFFECTIVELY REDUCES MULTIPLE PROTEINS ASSOCIATED WITH B-, T-, AND DENDRITIC CELL BIOMARKERS IN SJӦGREN’S DISEASE: CORROBORATION OF IMMUNOPHENOTYPING FINDINGS FROM THE ALISS PHASE 2 STUDY." Annals of the Rheumatic Diseases, vol. 83, no. Suppl 1, 2024, pp. 126-127, https://doi.org/10.1136/annrheumdis-2024-eular.2599.